A股異動 | 美迪西漲5% 獲調入科創50指數 2021年淨利同比增118%
格隆匯2月28日丨美迪西(688202.SH)現漲5.12%,報388.5元,總市值241億元。美迪西26日發佈業績快報,2021年營業收入為11.67億元,同比增長75.27%;歸母淨利潤2.82億元,同比增長117.93%;基本每股收益4.55元。報吿期內,受益於國家對醫藥產業政策鼓勵力度的不斷加大,以及製藥企業對創新藥物研發投入的持續提升,公司在優化業務結構的同時,緊緊把握臨牀前CRO市場的發展機遇,客户開拓能力和訂單承接能力同步提升。另外,根據指數規則,上海證券交易所與中證指數有限公司決定調整科創50指數樣本,自2022年3月11日收市後生效。調入和輝光電、納微科技、百克生物、美迪西、威高骨科5只證券。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.